Direct interference of HIV protease inhibitors with pancreatic β-cell function

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 369, Issue 6, 2004, Pages 583-590

  Dufer M ^a   Neye, Y ^a   Krippeit Drews, P ^a   Drews, G ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Cytosolic Ca2+ concentration; HIV protease inhibitors; Insulin secretion; Ion channels; Pancreatic cell; Ritonavir

Indexed keywords

4 AMINOPYRIDINE; GALLOPAMIL; GLUCOSE; INDINAVIR; ION CHANNEL; NELFINAVIR; POTASSIUM CHANNEL; PROTEINASE INHIBITOR; RITONAVIR; TOLBUTAMIDE; VOLTAGE GATED POTASSIUM CHANNEL;

ACTION POTENTIAL; ANIMAL CELL; ARTICLE; CALCIUM CURRENT; CELL FUNCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; INSULIN RELEASE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; POTASSIUM CURRENT; STIMULUS SECRETION COUPLING;

ANIMALS; CALCIUM; CALCIUM CHANNELS; CELLS, CULTURED; GLUCOSE; HIV PROTEASE INHIBITORS; INDINAVIR; INSULIN; ISLETS OF LANGERHANS; MEMBRANE POTENTIALS; MICE; NELFINAVIR; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS, VOLTAGE-GATED; RADIOIMMUNOASSAY; RITONAVIR;

EID: 3042552219     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-004-0933-6     Document Type: Article

References (34)

1. Anderson PL, Brundage RC, Bushman L, Kakuda TN, Remmel RP, Fletcher CV (2000) Indinavir plasma protein binding in HIV-1-infected adults. AIDS 14:2293-2297
2. Ashcroft FM, Rorsman P (1989) Electrophysiology of the pancreatic β-cell. Prog Biophys Mol Biol 54:87-143
3. Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA (2001) Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. AIDS 15:1057-1058
4. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, Stoll M, Schmidt RE (1999) Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13:F63-F70
5. Chen D, Misra A, Garg A (2002) Lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 87:4845-4856
6. Clement B (2001) HIV-Protease-Inhibitoren: state of the art. Pharmazie in unserer Zeit 30:208-211
7. Denissen JF, Grabowski BA, Johnson MK, Buko AM, Kempf DJ, Thomas SB, Surber BW (1997) Metabolism and disposition of the HIV-1 protease inhibitor ritonavir (ABT-538) in rats, dogs, and humans. Drug Metab Dispos 25:489-501
8. Dowell P, Flexner C, Kwiterovich PO, Lane MD (2000) Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 275:41325-41332
9. Gatti G, Di Biagio A, Casazza R, De Pascalis C, Bassetti M, Cruciani M, Vella S, Bassetti D (1999) The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 13:2083-2089
10. Germinario RJ, Colby-Germinario SP, Cammalleri C, Wainberg MA (2003) The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells. J Endocrinol 178:449-456
11. 2+ in single pancreatic β-cells. Biochem Biophys Res Commun 150:419-425
12. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450
13. + channels in the control of glucose-induced electrical activity in pancreatic B-cells. Pflügers Arch Eur J Physiol 416:568-572
14. Hruz PW, Murata H, Qiu H, Mueckler M (2002) Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 51:937-942
15. Koster JC, Remedi MS, Qiu H, Nichols CG, Hruz PW (2003) HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 52:1695-1700
16. Lee EC, Walmsley S, Fantus IG (1999) New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient. CMAJ 161:161-164
17. + channels in pancreatic beta cells: role, regulation and potential as therapeutic targets. Diabetologia 46:1046-1062
18. MacDonald PE, Ha XF, Wang J, Smukler SR, Sun AM, Gaisano HY, Salapatek AM, Backx PH, Wheeler MB (2001) Members of the Kv1 and Kv2 voltage-dependent K(+) channel families regulate insulin secretion. Mol Endocrinol 15:1423-1435
19. + channels in pancreatic beta-cells enhances glucose-dependent insulin secretion. J Biol Chem 277: 44938-44945
20. Murata H, Hruz PW, Mueckler M (2000) The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 275:20251-20254
21. Nolte LA, Yarasheski KE, Kawanaka K, Fisher J, Le N, Holloszy JO (2001) The HIV protease inhibitor indinavir decreases insulin- and contraction- stimulated glucose transport in skeletal muscle. Diabetes 50:1397-1401
22. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C (2001) Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 15:F11-F18
23. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M, Grunfeld C (2002) Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 16:F1-F8
24. Plant TD (1988) Properties and calcium-dependent inactivation of calcium currents in cultured mouse pancreatic B-cells. J Physiol 404:731-747
25. + channels. Role in stimulus-secretion coupling. J Biol Chem 271:32241-32246
26. Rudich A, Konrad D, Torok, D, Ben-Romano R, Huang C, Niu W, Garg RR, Wijesekara N, Germinario RJ, Bilan PJ, Klip A (2003) Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues. Diabetologia 46:649-658
27. Schutt M, Meier M, Meyer M, Klein J, Aries SP, Klein HH (2000) The HIV-1 protease inhibitor indinavir impairs insulin signalling in HepG2 hepatoma cells. Diabetologia 43:1145-1148
28. Shetty BV, Kosa MB, Khalil DA, Webber S (1996) Preclinical pharmacokinetics and distribution to tissue of AG1343, an inhibitor of human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 40:110-114
29. + channels in the insulin-secreting cell line INS-1. Pflügers Arch Eur J Physiol 442:49-56
30. + channel in mouse pancreatic beta-cells. Pflügers Arch-Eur J Physiol 407:493-499
31. Tsiodras S, Mantzoros C, Hammer S, Samore M (2000) Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 160: 2050-2056
32. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL, Gerich JE (2003) Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimes. Diabetes 52:918-925
33. Yarasheski KE, Tebas P, Sigmund C, Dagogo-Jack S, Bohrer A, Turk J, Halban PA, Cryer PE, Powderly WG (1999) Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 21:209-216
34. Zhou Z, Misler S (1996) Amperometric detection of quantal secretion from patch-clamped rat pancreatic beta-cell. J Biol Chem 271:270-277